Signalling pathways involved in endocrine resistance in breast cancer and associations with epithelial to mesenchymal transition (Review)

被引:80
作者
Al Saleh, Sanaa [1 ,2 ]
Sharaf, Leyla H. [1 ]
Luqmani, Yunus A. [1 ]
机构
[1] Kuwait Univ, Fac Pharm, Safat 13110, Kuwait
[2] Kuwait Univ, Coll Grad Studies, Safat 13110, Kuwait
关键词
breast cancer; endocrine resistance; epithelial to mesenchymal transition; signal transduction; ESTROGEN-RECEPTOR-ALPHA; EPIDERMAL-GROWTH-FACTOR; NF-KAPPA-B; PLASMINOGEN-ACTIVATOR SYSTEM; MAP KINASE PATHWAY; GENE-EXPRESSION; ANTIESTROGEN RESISTANCE; E-CADHERIN; CYCLIN D1; TAMOXIFEN RESISTANCE;
D O I
10.3892/ijo.2011.942
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Both de novo and acquired endocrine resistance constitute a major therapeutic problem for treatment of hormone-positive breast cancer. Multiple explanatory mechanisms have been proposed through the study of cellular models which focus principally on receptor tyrosine kinase mediated signalling pathways utilizing SRC, PI3K, MAPK and WADS. Many of the transducing molecules, particularly nuclear transcription factors such as SNAIL, TWIST, SNAIL2, ZEB FOXC2, TCF/LEF and GOOSECOID are participants in proliferation as well as invasion and metastasis, involving a process of orchestrated cellular remodeling which is being likened to the process of epithelial to mesenchymal transition that takes place during embryonic development. We review the accumulating evidence that points towards the occurrence of this phenomenon as a consequence of the loss of endocrine control, with both processes being similarly characterized by depletion of cell adhesion proteins, E-cadherin, catenins and cytokeratins, increased association with the extracellular matrix through induction of metalloproteinases, fibronectin and collagen, and a switch to a mobile vimentin-based cytoskeletal structure with loss of apical basal polarity.
引用
收藏
页码:1197 / 1217
页数:21
相关论文
共 296 条
[1]   The transcription factor ZEB1 (δEF1) promotes tumour cell dedifferentiation by repressing master regulators of epithelial polarity [J].
Aigner, K. ;
Dampier, B. ;
Descovich, L. ;
Mikula, M. ;
Sultan, A. ;
Schreiber, M. ;
Mikulits, W. ;
Brabletz, T. ;
Strand, D. ;
Obrist, P. ;
Sommergruber, W. ;
Schweifer, N. ;
Wernitznig, A. ;
Beug, H. ;
Foisner, R. ;
Eger, A. .
ONCOGENE, 2007, 26 (49) :6979-6988
[2]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[3]  
ALAZMI A, 2006, THESIS KUWAIT U
[4]   Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[5]   Meta-Analysis and Gene Set Enrichment Relative to ER Status Reveal Elevated Activity of MYC and E2F in the "Basal" Breast Cancer Subgroup [J].
Alles, M. Chehani ;
Gardiner-Garden, Margaret ;
Nott, David J. ;
Wang, Yixin ;
Foekens, John A. ;
Sutherland, Robert L. ;
Musgrove, Elizabeth A. ;
Ormandy, Christopher J. .
PLOS ONE, 2009, 4 (03)
[6]  
ALSALEH S, 2010, THESIS KUWAIT U
[7]  
Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO
[8]  
2-Z
[9]   THE ROLE OF JUN, FOS AND THE AP-1 COMPLEX IN CELL-PROLIFERATION AND TRANSFORMATION [J].
ANGEL, P ;
KARIN, M .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1072 (2-3) :129-157
[10]   AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer [J].
Anzick, SL ;
Kononen, J ;
Walker, RL ;
Azorsa, DO ;
Tanner, MM ;
Guan, XY ;
Sauter, G ;
Kallioniemi, OP ;
Trent, JM ;
Meltzer, PS .
SCIENCE, 1997, 277 (5328) :965-968